Published：May 31, 12:00Last updated：Jun 1, 00:44

Breakthrough Pancreatic Cancer Drug Doubles Survival

May. 31, 2026 12:00

A new once-daily pill, daraxonrasib, has almost doubled the survival time for patients with advanced pancreatic cancer compared to chemotherapy in a recent trial. The drug targets the mutated KRAS gene found in over 90% of pancreatic tumors, preventing further spread. Experts describe it as "landscape-changing" due to its effectiveness and fewer side effects. The trial involved 500 patients across North America, Europe, and Asia and was presented at the American Society of Clinical Oncology annual meeting in Chicago on May 31, 2026.

Summarized

8News

7Media

May. 31, 2026 17:05

On June 7, 2019, surgeons at the Centre Georges-François Leclerc in Dijon, France, performed a groundbreaking treatment using pressurized intraperitoneal aerosol chemotherapy (PIPAC) to reduce peritoneal metastases from pancreatic and biliary tract cancer. Unlike traditional chemotherapy, PIPAC is delivered as a pressurized aerosol under general anesthesia, minimizing harmful side effects. This innovative approach aims to improve survival rates for patients with pancreatic cancer.

Jun. 1, 2026 00:44

A new pill for pancreatic cancer patients has made headlines, offering hope for extended survival. Additionally, reports of singer Dua Lipa's wedding to Callum Turner have captured public attention. These stories were featured on Monday's front pages in 2026, reflecting significant medical and celebrity news.

A groundbreaking new drug, daraxonrasib, has nearly doubled the survival time for patients with advanced pancreatic cancer compared to traditional chemotherapy. The once-daily pill targets the mutated KRAS gene, found in over 90% of pancreatic tumors, effectively preventing further spread. Experts describe the treatment as "landscape-changing" due to its remarkable effectiveness and fewer side effects. The findings were presented at the American Society of Clinical Oncology annual meeting in Chicago on May 31, 2026, following a trial involving 500 patients across North America, Europe, and Asia.The Independent+2

🧬 Targeting the KRAS Gene

Daraxonrasib works by inhibiting the mutated KRAS protein, a key driver of tumor growth in pancreatic cancer. This mutation is present in the majority of cases, making the drug a highly targeted therapy. Unlike chemotherapy, which affects both healthy and cancerous cells, daraxonrasib specifically disrupts cancer cell proliferation, reducing collateral damage to the body.The Independent+1

🌍 Global Clinical Trials

The clinical trial spanned multiple continents, including North America, Europe, and Asia, involving 500 patients with advanced pancreatic cancer. Results showed a significant extension in survival time, with patients experiencing fewer side effects compared to traditional treatments. The trial's success has raised hopes for rapid regulatory approval and widespread availability.The Independent+2

💡 Innovative Treatment Approaches

In addition to daraxonrasib, other innovative treatments like pressurized intraperitoneal aerosol chemotherapy (PIPAC) are being explored. Developed at the Centre Georges-François Leclerc in Dijon, France, PIPAC delivers chemotherapy as a pressurized aerosol, minimizing harmful side effects while targeting peritoneal metastases. These advancements represent a new era in pancreatic cancer treatment.Le Monde+1

🚀 Future Implications

The development of daraxonrasib marks a significant milestone in cancer research, offering new hope for patients with one of the deadliest forms of cancer. Researchers are optimistic that further studies will confirm its efficacy, paving the way for its integration into standard treatment protocols. This breakthrough underscores the importance of continued investment in cancer research and innovation.Toronto Star+1

KRAS genedaraxonrasibpancreatic cancerCentre Georges-François LeclercAmerican Society of Clinical Oncology